← Oncology Approval Tracker

FDA DECISION ·

Xtandi tablets

enzalutamide · Astellas Pharma

FDA approvalNew formulationProstate cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

An oral tablet formulation for patients with castration-resistant prostate cancer or metastatic castration-sensitive prostate cancer.

LAMPGEN ANALYSIS

Why it matters

Added tablets as another dosage form for established enzalutamide indications.

What research teams should watch

Specify dosage form and strength in orders and reconcile androgen deprivation therapy.

PRIMARY RECORDS

Sources